Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2023 | 1 |
2024 | 3 |
Search Results
3 results
Results by year
Filters applied: . Clear all
Page 1
Impact of prior lenalidomide or proteasome inhibitor exposure on the effectiveness of ixazomib-lenalidomide-dexamethasone for relapsed/refractory multiple myeloma: A pooled analysis from the INSURE study.
Eur J Haematol. 2024 Apr 23. doi: 10.1111/ejh.14214. Online ahead of print.
Eur J Haematol. 2024.
PMID: 38654611
INSURE: a pooled analysis of ixazomib-lenalidomide-dexamethasone for relapsed/refractory myeloma in routine practice.
Leleu X, Lee HC, Zonder JA, Macro M, Ramasamy K, Hulin C, Silar J, Kuhn M, Ren K, Bent-Ennakhil N, Cherepanov D, Stull DM, Terpos E.
Leleu X, et al.
Future Oncol. 2024 May;20(14):935-950. doi: 10.2217/fon-2023-0604. Epub 2024 Jan 10.
Future Oncol. 2024.
PMID: 38197267
Free article.
Materials & methods: INSIGHT MM was a prospective study conducted in countries across Europe, Asia and North/Latin America while UVEA-IXA and REMIX were multicenter, retrospective/prospective studies conducted in Europe. ...
Materials & methods: INSIGHT MM was a prospective study conducted in countries across Europe, Asia and North/Latin America while …
Item in Clipboard
In-class transition from bortezomib-based therapy to IRd is an effective approach in newly diagnosed multiple myeloma.
Rifkin RM, Costello CL, Birhiray RE, Kambhampati S, Richter J, Abonour R, Lee HC, Stokes M, Ren K, Stull DM, Cherepanov D, Bogard K, Noga SJ, Girnius S.
Rifkin RM, et al.
Future Oncol. 2024 Jan;20(3):131-143. doi: 10.2217/fon-2023-0272. Epub 2023 Oct 9.
Future Oncol. 2024.
PMID: 37807952
Free article.
Item in Clipboard
Cite
Cite